La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Aclaris Therapeutics Gestione
Gestione criteri di controllo 4/4
Aclaris Therapeutics' Il CEO è Neal Walker, nominato in Jul2012, ha un mandato di 12.08 anni. possiede direttamente 1.9% delle azioni della società, per un valore di $ 1.61M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.2 anni e 10.3 anni.
Informazioni chiave
Neal Walker
Amministratore delegato
US$73.5k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 12.1yrs |
| Proprietà del CEO | 1.9% |
| Durata media del management | 2.2yrs |
| Durata media del Consiglio di amministrazione | 10.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$74k | n/a | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$115m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$6m | US$590k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$7m | US$567k | -US$91m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$65m |
| Dec 31 2020 | US$2m | US$424k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$3m | US$500k | -US$114m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$4m | US$550k | -US$82m |
| Sep 30 2018 | n/a | n/a | -US$81m |
| Jun 30 2018 | n/a | n/a | -US$79m |
| Mar 31 2018 | n/a | n/a | -US$86m |
| Dec 31 2017 | US$810k | US$510k | -US$50m |
Compensazione vs Mercato: La retribuzione totale di Neal ($USD 73.50K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).
Compensazione vs guadagni: La retribuzione di Neal è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Neal Walker (54 yo)
12.1yrs
Mandato
US$73,500
Compensazione
Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 12.1yrs | US$73.50k | 1.9% $ 1.6m | |
| Chief Financial Officer | 1.6yrs | US$2.34m | 0.034% $ 28.8k | |
| Chief Scientific Officer | 3.6yrs | US$2.26m | 0.26% $ 224.4k | |
| Chief Business Officer | 2.6yrs | US$2.33m | 0.048% $ 40.8k | |
| General Counsel & Corporate Secretary | 2.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Chemistry | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Project Leadership | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development | less than a year | Nessun dato | Nessun dato |
2.2yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di ACRS è considerato esperto (durata media dell'incarico 2.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 12.1yrs | US$73.50k | 1.9% $ 1.6m | |
| Independent Director | 4.6yrs | US$180.38k | 0.018% $ 15.0k | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 9.9yrs | US$194.38k | 0.061% $ 52.0k | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Lead Independent Director | 10.6yrs | US$206.88k | 0.075% $ 63.8k | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato |
10.3yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ACRS è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).